CART-ddBCMA

Overview

CART-ddBCMA is a BCMA directed CAR T cell therapy in development for multiple myeloma.

SparkCures ID 363
Developed By Arcellx, Inc.
Generic Name CART-ddBCMA
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

June 04, 2021

As previously announced, as of the April 14, 2021 data cutoff:

  • 12 of 12 patients achieved responses per IMWG criteria (median follow-up of 197 days; (Min – Max) 29-449 days)
    • 5 patients achieved stringent complete responses (sCR)
    • 1 patient achieved a complete response (CR)
    • 3 patients achieved very good partial responses (VGPR)
    • 3 patients achieved partial responses (PR)
  • One patient achieved VGPR despite prior progression on BCMA-targeted therapy
  • Responses in 11 patients are ongoing, with evidence that responses deepen over time

All patients enrolled in the study have poor prognostic factors with 10 of 12 patients penta-refractory and all 12 patients having had at least three prior treatments.

Resources